Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Large Increase in Short Interest

Azitra, Inc. (NYSEAMERICAN:AZTR) saw a significant growth in short interest in August. As of August 31st, there was short interest totaling 1,368,917 shares, a growth of 6,463.0% from the August 15th total of 20,858 shares. Approximately 2.3% of the company’s stock are short sold. Based on an average daily volume of 4,230,483 shares, the short-interest ratio is currently 0.3 days.

Azitra Trading Up 1.1%

NYSEAMERICAN AZTR traded up $0.00 during trading on Thursday, reaching $0.18. 545,541 shares of the company’s stock were exchanged, compared to its average volume of 9,161,490. The company’s fifty day simple moving average is $0.15 and its 200-day simple moving average is $0.19. Azitra has a fifty-two week low of $0.10 and a fifty-two week high of $1.09.

Azitra (NYSEAMERICAN:AZTR) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). As a group, analysts predict that Azitra will post -0.25 earnings per share for the current fiscal year.

About Azitra

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.